TL;DR

Psilocybin’s results in substance-use disorders are among the most cited in the field — but they come from full-dose trials with psychological support for alcohol and smoking, not from microdosing. The microdose-specific question is genuinely less settled: practitioner reports describe reported changes in craving intensity and substance-related behavior, but the formal evidence is early and observational. The honest framing is a striking full-dose signal alongside an honest microdose gap.

Why this matters

Addiction is one of the most compelling psilocybin stories in medicine, and also one of the easiest to misattribute to microdosing. The reputation rests on full-dose trials; the microdose practice is a separate, earlier-stage question. This page keeps the two distinct. A shorter version appears in the 90-second summary on iMicrodosing.net.

What the trials found

The clinical signal for psilocybin in addiction is one of the strongest in psychedelic medicine, but it comes almost entirely from full doses. A randomized clinical trial of psilocybin-assisted psychotherapy for alcohol use disorder reported reductions in heavy drinking days relative to placebo, [1] Clinical trial Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L (2022) doi:10.1001/jamapsychiatry.2022.2096 and an open-label pilot in nicotine-dependent smokers found that 12 of 15 participants were abstinent at six-month follow-up — reported outcomes that compared favorably with conventional cessation approaches within those studies. [2] Clinical trial Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) doi:10.1177/0269881114548296 It is worth being precise that addiction is heterogeneous: substance use disorders differ substantially across alcohol, nicotine, stimulants, opioids, and behavioral addictions, with different neurobiology, patterns of behavioral reinforcement, and treatment challenges — so a result in one does not automatically extend to the others. These are real and notable results, and they are full-dose, supported-session results — not evidence about microdosing. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706

What microdosing can and cannot claim

For microdosing specifically, the evidence is earlier and softer. Practitioner reports and surveys describe reduced craving intensity, more deliberate consumption, and shifts in substance-related and compulsive behavior — and the broad mood and wellbeing improvements seen in observational microdosing data are consistent with that. [4] Observational Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls Rootman JM, Kiraga M, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Walsh Z (2022) doi:10.1038/s41598-022-14512-3 But these are self-reported, uncontrolled observations: they document that people use microdosing for this purpose and perceive benefit, not that microdosing produces the outcome, and they say nothing reliable about craving regulation, relapse rates, or whether any effect would hold up as recovery support over time. [5] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204 Longitudinal microdosing research has also found that participants’ expectations are large and not well matched to what they actually report, which is a particular concern for a domain as expectation-sensitive as craving. [6] Observational A systematic study of microdosing psychedelics Polito V, Stevenson RJ (2019) doi:10.1371/journal.pone.0211023 A later review of controlled low-dose studies found some measurable effects relative to placebo in certain domains, which keeps the microdose question open without settling it for addiction — the same observational limits that constrain the wider use-case literature. [7] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research Polito V, Liknaitzky P (2024) doi:10.1177/02698811241254831

Key concepts
Full-dose led

The headline addiction results are full-dose, supported-session trials. That is where the strong signal lives; microdosing has not been tested to the same standard. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706

Reported craving change

Microdosers commonly report reduced cravings and altered substance relationships. This is consistent observational data, not demonstrated efficacy. [5] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204

Serious-condition caution

Substance use disorders warrant professional care, and some substances are dangerous to stop abruptly. Microdosing is not framed here as a taper or a treatment.

Three things to keep straight

First, the striking results are full-dose results; the microdose evidence is earlier and observational. Second, reduced-craving reports are real as reports but unproven as effects. [4] Observational Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls Rootman JM, Kiraga M, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, Walsh Z (2022) doi:10.1038/s41598-022-14512-3 Third, this is a serious-condition use case where the safety floor — professional care, no abrupt cessation of dangerous substances — matters more than the upside narrative.

Where addiction sits among the use cases

Addiction sits in the moderate tier, and the qualifier “full-dose led” carries the meaning: its reputation is borrowed from a strong adjacent literature, while its microdose-specific evidence resembles the early tier. It is a clear instance of the cluster-wide pattern in which the strength of full-dose psychedelic research can make a microdosing claim look more established than the microdose data alone supports. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706

Does microdosing help with addiction?

The striking addiction results come from full-dose trials for alcohol and smoking, not from microdosing. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706 Microdose-specific evidence is earlier: reports describe reduced cravings, but cannot establish that microdosing produces those outcomes. [5] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204

What did the full-dose addiction trials actually show?

Trials of full-dose psilocybin with psychological support reported effects on alcohol use disorder and smoking cessation larger than conventional aids in those studies — full doses in supervised settings, a different intervention from microdosing. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706

Is microdosing a safe way to taper off a substance?

This page does not frame microdosing as a tapering tool or treatment. Substance use disorders are serious and warrant professional care, and some substances are dangerous to stop abruptly. [5] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019) doi:10.1177/0269881119857204

In summary

Addiction has one of the most impressive full-dose psychedelic literatures and one of the more honest microdose gaps. The alcohol and smoking trials that anchor its reputation used full doses with psychological support and are not microdosing evidence; the microdose-specific picture is reduced-craving reports that are consistent, observational, and unproven. Layered on top is a real safety floor, because some of the substances in question are dangerous to stop without medical care. The defensible reading is to respect the full-dose signal, treat the microdose reports as early and unconfirmed, and keep professional treatment at the centre.